0000200406FALSE00002004062023-07-242023-07-240000200406us-gaap:CommonStockMember2023-07-242023-07-240000200406jnj:A0650NotesDueMay2024Member2023-07-242023-07-240000200406jnj:A550NotesDueNovember2024Member2023-07-242023-07-240000200406jnj:A1150NotesDueNovember2028Member2023-07-242023-07-240000200406jnj:A1650NotesDueMay2035Member2023-07-242023-07-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
July 24, 2023
Johnson & Johnson
(Exact name of registrant as specified in its charter)
| | | | | | | | |
New Jersey | 1-3215 | 22-1024240 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
732-524-0400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, Par Value $1.00 | JNJ | New York Stock Exchange |
0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange |
5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange |
1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange |
1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange |
Item 8.01 Other Events
The information contained in Exhibit 99.1 is hereby incorporated by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| | | | | | | | |
Exhibit No. | | Description of Exhibit |
| | |
99.1 | | |
| | |
104 | | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | | | | |
| | | Johnson & Johnson |
| | | | (Registrant) |
| | | | |
| | | | |
Date: | July 24, 2023 | | By: | /s/ Robert J. Decker, Jr. |
| | | | Robert J. Decker, Jr. Controller (Principal Accounting Officer) |
The following are certain preliminary results of selected unaudited financial and other information of Johnson & Johnson for the fiscal three and six months ended July 2, 2023 and actual unaudited financial results of Johnson & Johnson for the three and six months ended July 3, 2022. Johnson & Johnson has provided certain preliminary results below; however, its closing procedures for the fiscal three and six months ended July 2, 2023 are not yet complete. Johnson & Johnson’s actual results for the fiscal three and six months ended July 2, 2023 remain subject to the completion of management’s final review and Johnson & Johnson’s other closing procedures, or subsequent events, as well as the completion of the review of Johnson & Johnson’s financial statements. Accordingly, you should not place undue reliance on these preliminary results set out below, which may differ from actual results. During the course of the preparation of Johnson & Johnson’s unaudited consolidated financial statements and the notes thereto, additional items that require adjustments to the preliminary results presented below may be identified.
The preliminary financial data of Johnson & Johnson included below has been prepared by, and is the responsibility of, Johnson & Johnson’s management. Johnson & Johnson's independent registered public accounting firm, PricewaterhouseCoopers LLP, has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto.
The preliminary and actual results of Johnson & Johnson provided below do not represent a comprehensive statement of Johnson & Johnson’s financial results and should not be viewed as a substitute for unaudited consolidated financial results prepared in accordance with GAAP. In addition, the preliminary results for the fiscal three and six months ended July 2, 2023 are not necessarily indicative of the results to be achieved in any future period.
OVERALL FINANCIAL RESULTS:
| | | | | | | | | | | |
| Q2 |
($ in Millions, except EPS) | 2023 (Preliminary) | 2022 (Actual) | % Change |
Reported Sales | $25,530 | $24,020 | 6.3% |
Net Earnings/(Loss) | $5,144 | $4,814 | 6.9% |
EPS (diluted) | $1.96 | $1.80 | 8.9% |
REGIONAL SALES RESULTS:
| | | | | | | | | | | |
Q2 | | | % Change |
($ in Millions) | 2023 (Preliminary) | 2022 (Actual) | Reported |
U.S. | $13,444 | $12,197 | 10.2% |
International | 12,086 | 11,823 | 2.2 |
Worldwide | $25,530 | $24,020 | 6.3% |
Note: values may have been rounded
SEGMENT SALES RESULTS:
| | | | | | | | | | | |
Q2 | | | % Change |
($ in Millions) | 2023 (Preliminary) | 2022 (Actual) | Reported |
Consumer Health | $4,011 | $3,805 | 5.4% |
Pharmaceutical | 13,731 | 13,317 | 3.1 |
MedTech | 7,788 | 6,898 | 12.9 |
Worldwide | $25,530 | $24,020 | 6.3% |
Note: Values may have been rounded
| | |
Johnson & Johnson and Subsidiaries |
Supplementary Sales Data |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
(Unaudited; Dollars in Millions) | | SECOND QUARTER | | |
| | | | | | Percent Change | | |
| | 2023 (Preliminary) | | 2022 (Actual) | | Total | | |
Sales to customers by | | | | | | | | |
geographic area | | | | | | | | |
| | | | | | | | |
U.S. | | $ | 13,444 | | | 12,197 | | | 10.2 | % | | |
| | | | | | | | |
Europe | | 5,894 | | | 6,085 | | | (3.1) | | | |
Western Hemisphere excluding U.S. | | 1,713 | | | 1,536 | | | 11.5 | | | |
Asia-Pacific, Africa | | 4,479 | | | 4,202 | | | 6.6 | | | |
International | | 12,086 | | | 11,823 | | | 2.2 | | | |
| | | | | | | | |
Worldwide | | $ | 25,530 | | | 24,020 | | | 6.3 | % | | |
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
| | |
Johnson & Johnson and Subsidiaries |
Supplementary Sales Data |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
(Unaudited; Dollars in Millions) | | SIX MONTHS | | |
| | | | | | Percent Change | | |
| | 2023 (Preliminary) | | 2022 (Actual) | | Total | | |
Sales to customers by | | | | | | | | |
geographic area | | | | | | | | |
| | | | | | | | |
U.S. | | $ | 25,961 | | | 23,611 | | | 10.0 | % | | |
| | | | | | | | |
Europe | | 12,226 | | | 12,109 | | | 1.0 | | | |
Western Hemisphere excluding U.S. | | 3,300 | | | 3,018 | | | 9.3 | | | |
Asia-Pacific, Africa | | 8,789 | | | 8,708 | | | 0.9 | | | |
International | | 24,315 | | | 23,835 | | | 2.0 | | | |
| | | | | | | | |
Worldwide | | $ | 50,276 | | | 47,446 | | | 6.0 | % | | |
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
| | |
Johnson & Johnson and Subsidiaries |
Supplementary Sales Data |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(Unaudited; Dollars in Millions) | | SECOND QUARTER | | SIX MONTHS |
| | | | | | Percent Change | | | | | | Percent Change |
| | 2023 (Preliminary) | | 2022 (Actual) | | Total | | 2023 (Preliminary) | | 2022 (Actual) | | Total |
Sales to customers by | | | | | | | | | | | | |
segment of business | | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
Consumer Health | | | | | | | | | | | | |
U.S. | | $ | 1,787 | | | 1,687 | | | 6.0 | % | | $ | 3,522 | | | 3,244 | | | 8.6 | % |
International | | 2,224 | | | 2,118 | | | 5.0 | | | 4,341 | | | 4,147 | | | 4.7 | |
| | 4,011 | | | 3,805 | | | 5.4 | | | 7,863 | | | 7,391 | | | 6.4 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
Pharmaceutical (1) | | | | | | | | | | | | |
U.S. | | 7,818 | | | 7,159 | | | 9.2 | | | 14,841 | | | 13,791 | | | 7.6 | |
International | | 5,913 | | | 6,158 | | | (4.0) | | | 12,303 | | | 12,395 | | | (0.7) | |
| | 13,731 | | | 13,317 | | | 3.1 | | | 27,144 | | | 26,186 | | | 3.7 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
Pharmaceutical excluding COVID-19 Vaccine (1) | | | | | | | | | | | | |
U.S. | | 7,818 | | | 7,114 | | | 9.9 | | | 14,841 | | | 13,671 | | | 8.6 | |
International | | 5,628 | | | 5,659 | | | (0.5) | | | 11,271 | | | 11,514 | | | (2.1) | |
| | 13,446 | | | 12,773 | | | 5.3 | | | 26,112 | | | 25,185 | | | 3.7 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
MedTech | | | | | | | | | | | | |
U.S. | | 3,839 | | | 3,351 | | | 14.6 | | | 7,598 | | | 6,576 | | | 15.5 | |
International | | 3,949 | | | 3,547 | | | 11.3 | | | 7,671 | | | 7,293 | | | 5.2 | |
| | 7,788 | | | 6,898 | | | 12.9 | | | 15,269 | | | 13,869 | | | 10.1 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
U.S. | | 13,444 | | | 12,197 | | | 10.2 | | | 25,961 | | | 23,611 | | | 10.0 | |
International | | 12,086 | | | 11,823 | | | 2.2 | | | 24,315 | | | 23,835 | | | 2.0 | |
Worldwide | | 25,530 | | | 24,020 | | | 6.3 | | | 50,276 | | | 47,446 | | | 6.0 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
U.S. | | 13,444 | | | 12,152 | | | 10.6 | | | 25,961 | | | 23,491 | | | 10.5 | |
International | | 11,801 | | | 11,324 | | | 4.2 | | | 23,283 | | | 22,954 | | | 1.4 | |
Worldwide excluding COVID-19 Vaccine (1) | | $ | 25,245 | | | 23,476 | | | 7.5 | % | | $ | 49,244 | | | 46,445 | | | 6.0 | % |
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1)Refer to supplemental sales reconciliation schedules.
| | |
Johnson & Johnson and Subsidiaries |
Condensed Consolidated Statement of Earnings |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(Unaudited; in Millions Except Per Share Figures) | | SECOND QUARTER |
| | | | | | | | | | |
| | 2023 (Preliminary) | | 2022 (Actual) | | Percent Increase (Decrease) |
| | Amount | | Percent to Sales | | Amount | | Percent to Sales | |
Sales to customers | | $ | 25,530 | | | 100.0 | | | $ | 24,020 | | | 100.0 | | | 6.3 | |
Cost of products sold | | 8,212 | | | 32.2 | | | 7,919 | | | 33.0 | | | 3.7 | |
Gross Profit | | 17,318 | | | 67.8 | | | 16,101 | | | 67.0 | | | 7.6 | |
Selling, marketing and administrative expenses | | 6,665 | | | 26.1 | | | 6,226 | | | 25.9 | | | 7.1 | |
Research and development expense | | 3,829 | | | 15.0 | | | 3,703 | | | 15.4 | | | 3.4 | |
Interest (income) expense, net | | (23) | | | (0.1) | | | (26) | | | (0.1) | | | |
Other (income) expense, net* | | (60) | | | (0.2) | | | 273 | | | 1.1 | | | |
Restructuring | | 145 | | | 0.5 | | | 85 | | | 0.4 | | | |
Earnings before provision for taxes on income | | 6,762 | | | 26.5 | | | 5,840 | | | 24.3 | | | 15.8 | |
Provision for taxes on income | | 1,618 | | | 6.4 | | | 1,026 | | | 4.3 | | | 57.7 | |
Net earnings | | $ | 5,144 | | | 20.1 | | | $ | 4,814 | | | 20.0 | | | 6.9 | |
| | | | | | | | | | |
Net earnings per share (Diluted) | | $ | 1.96 | | | | | $ | 1.80 | | | | | 8.9 | |
| | | | | | | | | | |
Average shares outstanding (Diluted) | | 2,625.7 | | | | | 2,667.9 | | | | | |
| | | | | | | | | | |
Effective tax rate | | 23.9 | % | | | | 17.6 | % | | | | |
* Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.
| | |
Johnson & Johnson and Subsidiaries |
Condensed Consolidated Statement of Earnings |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(Unaudited; in Millions Except Per Share Figures) | | SIX MONTHS |
| | | | | | | | | | |
| | 2023 (Preliminary) | | 2022 (Actual) | | Percent Increase (Decrease) |
| | Amount | | Percent to Sales | | Amount | | Percent to Sales | |
Sales to customers | | $ | 50,276 | | | 100.0 | | | $ | 47,446 | | | 100.0 | | | 6.0 | |
Cost of products sold | | 16,607 | | | 33.0 | | | 15,517 | | | 32.7 | | | 7.0 | |
Gross Profit | | 33,669 | | | 67.0 | | | 31,929 | | | 67.3 | | | 5.4 | |
Selling, marketing and administrative expenses | | 12,803 | | | 25.5 | | | 12,164 | | | 25.6 | | | 5.3 | |
Research and development expense | | 7,392 | | | 14.7 | | | 7,165 | | | 15.1 | | | 3.2 | |
In-process research and development | | 49 | | | 0.1 | | | 610 | | | 1.3 | | | |
Interest (income) expense, net | | (43) | | | (0.1) | | | (38) | | | (0.1) | | | |
Other (income) expense, net* | | 7,168 | | | 14.3 | | | 171 | | | 0.4 | | | |
Restructuring | | 275 | | | 0.5 | | | 155 | | | 0.3 | | | |
Earnings before provision for taxes on income | | 6,025 | | | 12.0 | | | 11,702 | | | 24.7 | | | (48.5) | |
Provision for taxes on income | | 949 | | | 1.9 | | | 1,739 | | | 3.7 | | | (45.4) | |
Net earnings | | $ | 5,076 | | | 10.1 | | | $ | 9,963 | | | 21.0 | | | (49.1) | |
| | | | | | | | | | |
Net earnings per share (Diluted) | | $ | 1.93 | | | | | $ | 3.73 | | | | | (48.3) | |
| | | | | | | | | | |
Average shares outstanding (Diluted) | | 2,630.7 | | | | | 2,669.2 | | | | | |
| | | | | | | | | | |
Effective tax rate | | 15.8 | % | | | | 14.9 | % | | | | |
* Fiscal six months Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| SECOND QUARTER | | | | SIX MONTHS | | |
| | | | | % Change | | | | | | % Change |
| 2023 (Preliminary) | | 2022 (Actual) | | Reported | | 2023 (Preliminary) | | 2022 (Actual) | | Reported |
CONSUMER HEALTH SEGMENT (1) | | | | | | | | | | | |
| | | | | | | | | | | |
OTC | | | | | | | | | | | |
US | $ | 712 | | | 663 | | | 7.5 | % | | $ | 1,457 | | | 1,333 | | | 9.3 | % |
Intl | 947 | | | 818 | | | 15.7 | | | 1,844 | | | 1,609 | | | 14.6 | |
WW | 1,659 | | | 1,482 | | | 12.0 | | | 3,301 | | | 2,943 | | | 12.2 | |
| | | | | | | | | | | |
SKIN HEALTH / BEAUTY | | | | | | | | | | | |
US | 650 | | | 629 | | | 3.4 | | | 1,267 | | | 1,173 | | | 8.0 | |
Intl | 498 | | | 497 | | | 0.3 | | | 991 | | | 965 | | | 2.7 | |
WW | 1,148 | | | 1,126 | | | 2.0 | | | 2,258 | | | 2,138 | | | 5.6 | |
| | | | | | | | | | | |
ORAL CARE | | | | | | | | | | | |
US | 173 | | | 170 | | | 1.7 | | | 332 | | | 313 | | | 6.2 | |
Intl | 225 | | | 224 | | | 0.3 | | | 427 | | | 447 | | | (4.7) | |
WW | 398 | | | 394 | | | 0.9 | | | 759 | | | 760 | | | (0.2) | |
| | | | | | | | | | | |
BABY CARE | | | | | | | | | | | |
US | 99 | | | 88 | | | 12.5 | | | 195 | | | 173 | | | 12.7 | |
Intl | 261 | | | 287 | | | (9.1) | | | 524 | | | 557 | | | (6.0) | |
WW | 360 | | | 375 | | | (4.0) | | | 719 | | | 730 | | | (1.6) | |
| | | | | | | | | | | |
WOMEN'S HEALTH | | | | | | | | | | | |
US | 4 | | | 3 | | | (2.1) | | | 7 | | | 7 | | | (0.1) | |
Intl | 235 | | | 228 | | | 3.5 | | | 449 | | | 452 | | | (0.7) | |
WW | 238 | | | 230 | | | 3.4 | | | 455 | | | 458 | | | (0.6) | |
| | | | | | | | | | | |
WOUND CARE / OTHER | | | | | | | | | | | |
US | 149 | | | 133 | | | 12.3 | | | 264 | | | 245 | | | 7.9 | |
Intl | 58 | | | 65 | | | (10.3) | | | 107 | | | 117 | | | (8.4) | |
WW | 207 | | | 197 | | | 4.9 | | | 371 | | | 361 | | | 2.6 | |
| | | | | | | | | | | |
TOTAL CONSUMER HEALTH | | | | | | | | | | | |
US | 1,787 | | | 1,687 | | | 6.0 | | | 3,522 | | | 3,244 | | | 8.6 | |
Intl | 2,224 | | | 2,118 | | | 5.0 | | | 4,341 | | | 4,147 | | | 4.7 | |
WW | $ | 4,011 | | | 3,805 | | | 5.4 | % | | $ | 7,863 | | | 7,391 | | | 6.4 | % |
| | | | | | | | | | | |
| | | | | | | | | | | |
See footnotes at end of schedule
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | SECOND QUARTER | | SIX MONTHS |
| | | | | | | % Change | | | | | | % Change |
| | | 2023 (Preliminary) | | 2022 (Actual) | | Reported | | 2023 (Preliminary) | | 2022 (Actual) | | Reported |
PHARMACEUTICAL SEGMENT (1) (2) | | |
| | | | | | | | | | | | | |
IMMUNOLOGY | | |
US | | $ | 2,865 | | | 2,853 | | | 0.4 | % | | $ | 5,313 | | | 5,354 | | | (0.8) | % |
Intl | | 1,631 | | | 1,559 | | | 4.7 | | | 3,295 | | | 3,176 | | | 3.8 | |
WW | | 4,496 | | | 4,411 | | | 1.9 | | | 8,608 | | | 8,530 | | | 0.9 | |
| REMICADE | | | | | | | | | | | | |
| US | | 277 | | | 391 | | | (29.3) | | | 553 | | | 749 | | | (26.2) | |
| US Exports (3) | | 33 | | | 44 | | | (24.9) | | | 74 | | | 124 | | | (40.3) | |
| Intl | | 152 | | | 212 | | | (28.2) | | | 322 | | | 437 | | | (26.2) | |
| WW | | 462 | | | 647 | | | (28.6) | | | 949 | | | 1,310 | | | (27.5) | |
| SIMPONI / SIMPONI ARIA | | | | | | | | | | | | |
| US | | 285 | | | 301 | | | (5.1) | | | 556 | | | 588 | | | (5.4) | |
| Intl | | 244 | | | 266 | | | (8.2) | | | 510 | | | 549 | | | (7.1) | |
| WW | | 529 | | | 566 | | | (6.6) | | | 1,066 | | | 1,137 | | | (6.2) | |
| STELARA | | | | | | | | | | | | |
| US | | 1,817 | | | 1,731 | | | 4.9 | | | 3,268 | | | 3,110 | | | 5.1 | |
| Intl | | 981 | | | 868 | | | 13.0 | | | 1,974 | | | 1,777 | | | 11.1 | |
| WW | | 2,797 | | | 2,599 | | | 7.6 | | | 5,241 | | | 4,887 | | | 7.2 | |
| TREMFYA | | | | | | | | | | | | |
| US | | 450 | | | 382 | | | 17.8 | | | 856 | | | 773 | | | 10.7 | |
| Intl | | 255 | | | 214 | | | 19.4 | | | 489 | | | 413 | | | 18.4 | |
| WW | | 706 | | | 597 | | | 18.3 | | | 1,346 | | | 1,187 | | | 13.4 | |
| OTHER IMMUNOLOGY | | | | | | | | | | | | |
| US | | 4 | | | 3 | | | 17.8 | | | 7 | | | 9 | | | (30.2) | |
| Intl | | 0 | | | 0 | | | — | | | 0 | | | 0 | | | — | |
| WW | | 4 | | | 3 | | | 17.8 | | | 7 | | | 9 | | | (30.2) | |
| | | | | | | | | | | | | |
INFECTIOUS DISEASES | | | | | | | | | | | | |
US | | 395 | | | 415 | | | (4.9) | | | 787 | | | 876 | | | (10.2) | |
Intl | | 727 | | | 901 | | | (19.4) | | | 1,920 | | | 1,737 | | | 10.5 | |
WW | | 1,121 | | | 1,316 | | | (14.8) | | | 2,707 | | | 2,613 | | | 3.6 | |
| COVID-19 VACCINE | | | | | | | | | | | | |
| US | | — | | | 45 | | | * | | — | | | 120 | | | * |
| Intl | | 285 | | | 499 | | | (43.0) | | | 1,032 | | | 881 | | | 17.1 | |
| WW | | 285 | | | 544 | | | (47.7) | | | 1,032 | | | 1,001 | | | 3.0 | |
| EDURANT / rilpivirine | | | | | | | | | | | | |
| US | | 8 | | | 9 | | | (9.0) | | | 17 | | | 18 | | | (5.3) | |
| Intl | | 258 | | | 215 | | | 19.9 | | | 529 | | | 454 | | | 16.4 | |
| WW | | 266 | | | 225 | | | 18.6 | | | 546 | | | 473 | | | 15.6 | |
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | | | | | | | | | | | | |
| US | | 382 | | | 355 | | | 7.6 | | | 760 | | | 724 | | | 5.0 | |
| Intl | | 109 | | | 110 | | | (0.2) | | | 208 | | | 242 | | | (13.9) | |
| WW | | 491 | | | 464 | | | 5.8 | | | 968 | | | 965 | | | 0.3 | |
| OTHER INFECTIOUS DISEASES | | | | | | | | | | | | |
| US | | 5 | | | 6 | | | (27.2) | | | 10 | | | 14 | | | (30.6) | |
| Intl | | 74 | | | 77 | | | (3.5) | | | 151 | | | 160 | | | (5.6) | |
| WW | | 79 | | | 83 | | | (5.2) | | | 161 | | | 174 | | | (7.6) | |
See footnotes at end of schedule
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | SECOND QUARTER | | SIX MONTHS |
| | | | | | | | | | % Change | | | | | | % Change |
| | | | | | 2023 (Preliminary) | | 2022 (Actual) | | Reported | | 2023 (Preliminary) | | 2022 (Actual) | | Reported |
PHARMACEUTICAL SEGMENT (1) (2) (Continued) | | |
| | | | | | | | | | | | | | | | |
NEUROSCIENCE | | |
US | | | | | $ | 1,029 | | | 896 | | | 14.9 | % | | $ | 2,007 | | | 1,739 | | | 15.4 | % |
Intl | | | | | 764 | | | 837 | | | (8.8) | | | 1,590 | | | 1,735 | | | (8.4) | |
WW | | | | | 1,793 | | | 1,734 | | | 3.5 | | | 3,597 | | | 3,475 | | | 3.5 | |
| CONCERTA / methylphenidate | | | | | | | | | | | | |
| US | | | 64 | | | 38 | | | 68.2 | | | 134 | | | 73 | | | 84.0 | |
| Intl | | | | | 143 | | | 123 | | | 16.3 | | | 279 | | | 245 | | | 13.9 | |
| WW | | | | | 208 | | | 161 | | | 28.6 | | | 414 | | | 318 | | | 30.0 | |
| INVEGA SUSTENNA / XEPLION / INVEGA | | | | | | | | | | | | |
| TRINZA / TREVICTA | | | | | | | | | | | | | |
| US | | | | | 721 | | | 691 | | | 4.3 | | | 1,434 | | | 1,352 | | | 6.0 | |
| Intl | | | | | 310 | | | 362 | | | (14.4) | | | 641 | | | 749 | | | (14.5) | |
| WW | | | | | 1,031 | | | 1,054 | | | (2.1) | | | 2,075 | | | 2,102 | | | (1.3) | |
| SPRAVATO | | | | | | | | | | | | | | |
| US | | | | | 144 | | | 74 | | | 93.2 | | | 255 | | | 135 | | | 88.3 | |
| Intl | | | | | 25 | | | 11 | | | * | | 45 | | | 20 | | | * |
| WW | | | | | 169 | | | 85 | | | 98.2 | | | 300 | | | 155 | | | 93.1 | |
| OTHER NEUROSCIENCE | | | | | | | | | | | | |
| US | | | | | 100 | | | 93 | | | 9.3 | | | 184 | | | 179 | | | 3.1 | |
| Intl | | | | | 286 | | | 341 | | | (16.4) | | | 625 | | | 721 | | | (13.4) |
| WW | | | | | 386 | | | 433 | | | (10.9) | | | 809 | | | 900 | | | (10.1) | |
| | | | | | | | | | | | | | | | |
ONCOLOGY | | | | | | | | | | | | | | |
US | | | | | 2,069 | | | 1,679 | | | 23.2 | | | 3,958 | | | 3,261 | | | 21.4 | |
Intl | | | | | 2,329 | | | 2,362 | | | (1.4) | | | 4,552 | | | 4,731 | | | (3.8) | |
WW | | | | | 4,398 | | | 4,042 | | | 8.8 | | | 8,510 | | | 7,992 | | | 6.5 | |
| CARVYKTI | | | | | | | | | | | | | | |
| US | | | | | 114 | | | 24 | | | * | | 184 | | | 24 | | | * |
| Intl | | | | | 3 | | | — | | | * | | 5 | | | — | | | * |
| WW | | | | | 117 | | | 24 | | | * | | 189 | | | 24 | | | * |
| DARZALEX | | | | | | | | | | | | | | |
| US | | | | | 1,322 | | | 1,021 | | | 29.5 | | | 2,513 | | | 1,974 | | | 27.3 |
| Intl | | | | | 1,110 | | | 965 | | | 15.0 | | | 2,182 | | | 1,868 | | | 16.8 |
| WW | | | | | 2,431 | | | 1,986 | | | 22.4 | | | 4,695 | | | 3,842 | | | 22.2 |
| ERLEADA | | | | | | | | | | | | | | |
| US | | | | | 241 | | | 233 | | | 3.6 | | | 490 | | | 439 | | | 11.8 | |
| Intl | | | | | 326 | | | 218 | | | 49.7 | | | 619 | | | 412 | | | 50.3 | |
| WW | | | | | 567 | | | 450 | | | 25.9 | | | 1,109 | | | 850 | | | 30.4 | |
| IMBRUVICA | | | | | | | | | | | | | | |
| US | | | | | 262 | | | 349 | | | (24.9) | | | 532 | | | 719 | | | (26.0) | |
| Intl | | | | | 579 | | | 620 | | | (6.7) | | | 1,136 | | | 1,288 | | | (11.8) | |
| WW | | | | | 841 | | | 970 | | | (13.2) | | | 1,668 | | | 2,008 | | | (16.9) | |
| ZYTIGA / abiraterone acetate | | | | | | | | | | | | |
| US | | | | | 9 | | | 19 | | | (55.2) | | | 25 | | | 38 | | | (34.7) | |
| Intl | | | | | 218 | | | 486 | | | (55.1) | | | 447 | | | 1,006 | | | (55.6) | |
| WW | | | | | 227 | | | 505 | | | (55.1) | | | 472 | | | 1,044 | | | (54.8) | |
| OTHER ONCOLOGY | | | | | | | | | | | | | |
| US | | | | | 122 | | | 33 | | | * | | 214 | | | 67 | | | * |
| Intl | | | | | 92 | | | 72 | | | 27.8 | | | 162 | | | 156 | | | 3.6 | |
| WW | | | | | 214 | | | 106 | | | * | | 376 | | | 224 | | | 68.0 | |
See footnotes at end of schedule
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | SECOND QUARTER | | SIX MONTHS |
| | | | | | | | | % Change | | | | | | % Change |
| | | | | 2023 (Preliminary) | | 2022 (Actual) | | Reported | | 2023 (Preliminary) | | 2022 (Actual) | | Reported |
PHARMACEUTICAL SEGMENT (1) (2) (Continued) | | |
| | | | | | | | | | | | | | | |
PULMONARY HYPERTENSION | | |
US | | | | $ | 684 | | | 560 | | | 22.0 | % | | $ | 1,284 | | | 1,132 | | | 13.4 | % |
Intl | | | | 289 | | | 284 | | | 2.0 | | | 561 | | | 563 | | | (0.4) | |
WW | | | | 972 | | | 843 | | | 15.3 | | | 1,844 | | | 1,695 | | | 8.8 | |
| OPSUMIT | | | | | | | | | | | | | |
| US | | | | 328 | | | 265 | | | 23.7 | | | 601 | | | 538 | | | 11.6 | |
| Intl | | | | 179 | | | 173 | | | 3.4 | | | 346 | | | 343 | | | 0.9 | |
| WW | | | | 507 | | | 438 | | | 15.7 | | | 947 | | | 881 | | | 7.5 | |
| UPTRAVI | | | | | | | | | | | | | |
| US | | | | 338 | | | 272 | | | 24.2 | | | 642 | | | 541 | | | 18.7 | |
| Intl | | | | 61 | | | 56 | | | 10.0 | | | 119 | | | 112 | | | 6.6 | |
| WW | | | | 399 | | | 328 | | | 21.8 | | | 761 | | | 653 | | | 16.6 | |
| OTHER PULMONARY HYPERTENSION | | | | | | | | | | | | |
| US | | | | 18 | | | 23 | | | (23.8) | | | 41 | | | 53 | | | (23.0) | |
| Intl | | | | 48 | | | 55 | | | (10.9) | | | 95 | | | 108 | | | (11.7) |
| WW | | | | 66 | | | 78 | | | (14.7) | | | 136 | | | 161 | | | (15.5) | |
| | | | | | | | | | | | | | | |
CARDIOVASCULAR / METABOLISM / OTHER | | | | | | | | | | | |
US | | | | 776 | | | 757 | | | 2.6 | | | 1,491 | | | 1,429 | | | 4.3 | |
Intl | | | | 174 | | | 215 | | | (19.0) | | | 386 | | | 453 | | | (14.7) | |
WW | | | | 950 | | | 972 | | | (2.2) | | | 1,877 | | | 1,882 | | | (0.3) | |
| XARELTO | | | | | | | | | | | | | |
| US | | | | 637 | | | 609 | | | 4.7 | | | 1,215 | | | 1,117 | | | 8.8 | |
| Intl | | | | — | | | — | | | — | | | — | | | — | | | — | |
| WW | | | | 637 | | | 609 | | | 4.7 | | | 1,215 | | | 1,117 | | | 8.8 | |
| OTHER | | | | | | | | | | | | | | |
| US | | | | 138 | | | 148 | | | (6.3) | | | 275 | | | 312 | | | (11.8) |
| Intl | | | | 174 | | | 215 | | | (19.0) | | | 386 | | | 453 | | | (14.7) |
| WW | | | | 313 | | | 363 | | | (13.8) | | | 662 | | | 765 | | | (13.5) |
| | | | | | | | | | | | | | | |
TOTAL PHARMACEUTICAL | | | | | | | | | | | | |
US | | | | 7,818 | | | 7,159 | | | 9.2 | | | 14,841 | | | 13,791 | | | 7.6 | |
Intl | | | | 5,913 | | | 6,158 | | | (4.0) | | | 12,303 | | | 12,395 | | | (0.7) | |
WW | | | | $ | 13,731 | | | 13,317 | | | 3.1 | % | | $ | 27,144 | | | 26,186 | | | 3.7 | % |
| | | | | | | | | | | | | | | |
See footnotes at end of schedule
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | SECOND QUARTER | | SIX MONTHS |
| | | | | | | | | | | % Change | | | | | | % Change |
| | | | | | | 2023 (Preliminary) | | 2022 (Actual) | | Reported | | 2023 (Preliminary) | | 2022 (Actual) | | Reported |
MEDTECH SEGMENT (1) (2) | | |
| | | | | | | | | | | | | | | | | |
INTERVENTIONAL SOLUTIONS | | |
US | | | | | | $ | 908 | | | 525 | | | 73.1 | % | | $ | 1,771 | | | 1,019 | | | 73.8 | % |
Intl | | | | | | 712 | | | 525 | | | 35.7 | | | 1,352 | | | 1,123 | | | 20.5 | |
WW | | | | | | 1,620 | | | 1,049 | | | 54.4 | | | 3,123 | | | 2,141 | | | 45.8 | |
| | | | | | | | | | | | | | | | | |
| ELECTROPHYSIOLOGY | | | | | | | | | | | | | |
| US | | | | | | 609 | | | 499 | | | 22.0 | | | 1,180 | | | 969 | | | 21.7 | |
| Intl | | | | | | 587 | | | 469 | | | 25.1 | | | 1,109 | | | 1,001 | | | 10.8 | |
| WW | | | | | | 1,196 | | | 968 | | | 23.5 | | | 2,288 | | | 1,970 | | | 16.2 | |
| | | | | | | | | | | | | | | | | |
| ABIOMED | | | | | | | | | | | | | | |
| US | | | | | | 272 | | | — | | | * | | 536 | | | — | | | * |
| Intl | | | | | | 59 | | | — | | | * | | 119 | | | — | | | * |
| WW | | | | | | 331 | | | — | | | * | | 655 | | | — | | | * |
| | | | | | | | | | | | | | | | | |
| OTHER INTERVENTIONAL SOLUTIONS | | | | | | | | | | | | |
| US | | | | | | 27 | | | 26 | | | 4.5 | | | 55 | | | 51 | | | 10.8 | |
| Intl | | | | | | 67 | | | 56 | | | 20.0 | | | 125 | | | 121 | | | 2.8 | |
| WW | | | | | | 93 | | | 81 | | | 15.1 | | | 180 | | | 171 | | | 5.1 | |
| | | | | | | | | | | | | | | | | |
ORTHOPAEDICS | | | | | | | | | | | | | |
US | | | | | | 1,388 | | | 1,338 | | | 3.7 | | | 2,751 | | | 2,627 | | | 4.7 | |
Intl | | | | | | 878 | | | 820 | | | 7.0 | | | 1,759 | | | 1,719 | | | 2.3 | |
WW | | | | | | 2,265 | | | 2,157 | | | 5.0 | | | 4,510 | | | 4,345 | | | 3.8 | |
| | | | | | | | | | | | | | | | | |
| HIPS | | | | | | | | | | | | | | | | |
| US | | | | | | 250 | | | 240 | | | 4.1 | | | 491 | | | 465 | | | 5.6 | |
| Intl | | | | | | 147 | | | 148 | | | (0.8) | | | 296 | | | 312 | | | (5.1) | |
| WW | | | | | | 397 | | | 388 | | | 2.2 | | | 787 | | | 777 | | | 1.3 | |
| | | | | | | | | | | | | | | | | |
| KNEES | | | | | | | | | | | | | | | |
| US | | | | | | 221 | | | 216 | | | 2.4 | | | 447 | | | 417 | | | 7.2 | |
| Intl | | | | | | 142 | | | 133 | | | 6.3 | | | 284 | | | 271 | | | 4.8 | |
| WW | | | | | | 363 | | | 349 | | | 3.9 | | | 731 | | | 688 | | | 6.3 | |
| | | | | | | | | | | | | | | | | |
| TRAUMA | | | | | | | | | | | | | | |
| US | | | | | | 483 | | | 464 | | | 4.3 | | | 974 | | | 939 | | | 3.7 | |
| Intl | | | | | | 255 | | | 232 | | | 9.9 | | | 522 | | | 505 | | | 3.2 | |
| WW | | | | | | 739 | | | 696 | | | 6.1 | | | 1,496 | | | 1,444 | | | 3.6 | |
| | | | | | | | | | | | | | | | | |
| SPINE, SPORTS & OTHER | | | | | | | | | | | | | |
| US | | | | | | 433 | | | 418 | | | 3.5 | | | 839 | | | 805 | | | 4.1 | |
| Intl | | | | | | 334 | | | 306 | | | 9.0 | | | 657 | | | 630 | | | 4.2 | |
| WW | | | | | | 766 | | | 724 | | | 5.8 | | | 1,495 | | | 1,436 | | | 4.2 | |
See footnotes at end of schedule
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | SECOND QUARTER | | SIX MONTHS |
| | | | | | | | | % Change | | | | | | % Change |
| | | | | 2023 (Preliminary) | | 2022 (Actual) | | Reported | | 2023 (Preliminary) | | 2022 (Actual) | | Reported |
| | | | | | | | | | | | | | | |
MEDTECH SEGMENT (1) (2) (Continued) | | |
SURGERY | | |
US | | | | $ | 1,015 | | | 992 | | | 2.2 | % | | $ | 1,990 | | | 1,913 | | | 4.0 | % |
Intl | | | | 1,580 | | | 1,458 | | | 8.4 | | | 3,039 | | | 2,971 | | | 2.3 | |
WW | | | | 2,594 | | | 2,450 | | | 5.9 | | | 5,028 | | | 4,884 | | | 3.0 | |
| ADVANCED | | | | | | | | | | | | | |
| US | | | | 466 | | | 454 | | | 2.7 | | | 910 | | | 871 | | | 4.5 | |
| Intl | | | | 757 | | | 702 | | | 7.8 | | | 1,430 | | | 1,431 | | | 0.0 | |
| WW | | | | 1,222 | | | 1,156 | | | 5.8 | | | 2,340 | | | 2,302 | | | 1.7 | |
| | | | | | | | | | | | | | | |
| GENERAL | | | | | | | | | | | | | | |
| US | | | | 548 | | | 538 | | | 1.9 | | | 1,079 | | | 1,042 | | | 3.6 | |
| Intl | | | | 823 | | | 756 | | | 8.9 | | | 1,608 | | | 1,540 | | | 4.5 | |
| WW | | | | 1,372 | | | 1,294 | | | 6.0 | | | 2,688 | | | 2,582 | | | 4.1 | |
| | | | | | | | | | | | | | | |
VISION | | | | | | | | | | | |
US | | | | 529 | | | 496 | | | 6.6 | | | 1,087 | | | 1,017 | | | 6.9 | |
Intl | | | | 778 | | | 745 | | | 4.6 | | | 1,521 | | | 1,481 | | | 2.7 | |
WW | | | | 1,308 | | | 1,241 | | | 5.4 | | | 2,608 | | | 2,498 | | | 4.4 | |
| | | | | | | | | | | | | | | |
| CONTACT LENSES / OTHER | | | | | | | | | | | | |
| US | | | | 409 | | | 374 | | | 9.1 | | | 853 | | | 774 | | | 10.1 | |
| Intl | | | | 530 | | | 519 | | | 2.2 | | | 1,039 | | | 1,030 | | | 0.9 | |
| WW | | | | 939 | | | 894 | | | 5.1 | | | 1,892 | | | 1,804 | | | 4.9 | |
| SURGICAL | | | | | | | | | | | | | |
| US | | | | 120 | | | 122 | | | (1.1) | | | 234 | | | 243 | | | (3.6) | |
| Intl | | | | 249 | | | 225 | | | 10.1 | | | 482 | | | 451 | | | 6.7 | |
| WW | | | | 369 | | | 347 | | | 6.2 | | | 716 | | | 694 | | | 3.1 | |
| | | | | | | | | | | | | | | |
TOTAL MEDTECH | | | | | | | | | | | | |
US | | | | 3,839 | | | 3,351 | | | 14.6 | | | 7,598 | | | 6,576 | | | 15.5 | |
Intl | | | | 3,949 | | | 3,547 | | | 11.3 | | | 7,671 | | | 7,293 | | | 5.2 | |
WW | | | | $ | 7,788 | | | 6,898 | | | 12.9 | % | | $ | 15,269 | | | 13,869 | | | 10.1 | % |
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1)Unaudited
(2)Certain prior year amounts have been reclassified to conform to current year product disclosures
(3)Reported as U.S. sales
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=jnj_A0650NotesDueMay2024Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=jnj_A550NotesDueNovember2024Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=jnj_A1150NotesDueNovember2028Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=jnj_A1650NotesDueMay2035Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jul 2023 to Jul 2024